# Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

> **NCT02436707** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 129 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Dexamethasone
- **DRUG:** Cisplatin
- **DRUG:** Mesna
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** G-CSF
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT02436707
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436707, "Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02436707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*